SLC2A1 and cancer: EGFR expression and downstream signaling pathways have shown positive correlations with Glut1 expression and membrane localization in lung cancer [54], pancreatic cancer tissue [55, 56], and triple-negative breast cancer (TNBC) [57], suggesting that TKI-sensitive cancer cells employ passive glucose transporters to engulf glucose and that downregulation of these transporters may account for the anticancer activity of TKIs.